Karyopharm Therapeutics | KPTI - Pre Tax Profit


Karyopharm Therapeutics reported $-39.9M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Abbott USD 2.36B 178M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
AstraZeneca USD 3.24B 117M Sep/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Incyte USD 389.94M 92.37M Dec/2025
J&J USD 4.97B 2.53B Dec/2025
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Merck USD 6.74B 22M Sep/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Novartis USD 4.64B 445M Dec/2025
Novartis USD 5.17B 637M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Takeda JPY 133.86B 105.69B Dec/2025
Tectonic Therapeutic USD -18.97M 63K Dec/2025
TG Therapeutics USD 45.09M 19.18M Dec/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Xencor USD -4.27M 1.76M Dec/2025